F8 and hemophilia: Inhibitory antibodies (inhibitors) against exogenous factor (F)VIII or IX concentrates interfere with their therapeutic potential in patients with hemophilia by blocking correction of FVIII/FIX-driven coagulation in case of treatment of bleeds or surgeries as well as effective prophylactic replacement therapy in patients with hemophilia.